NCT06678399
Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery
Phase: Phase 1/2
Role: Lead Sponsor
Start: Apr 1, 2025
Completion: Jan 1, 2027